NCT05660642View on ClinicalTrials.gov

An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Treatment Resistant Depression
Interventions
DRUG

BPL-003

Experimental BPL-003 arms: will investigate one of two doses of BPL-003 (Part 1) and two doses of BPL-003 (Part 2)

Trial Locations (3)

L34 1BH

MAC Clinical Research, Liverpool

Unknown

Hammersmith Medicines Research, London

King's College London, Clinical Trials Facility, London

Sponsors
All Listed Sponsors
lead

Beckley Psytech Limited

INDUSTRY

NCT05660642 - An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression | Biotech Hunter | Biotech Hunter